Polycystic Kidney Diseases

Autosomal Recessive Polycystic Kidney Disease (ARPKD)

Genetics and Pathophysiology

• Autosomal recessive polycystic kidney disease (ARPKD) is a severe, monogenic hepatorenal fibrocystic disorder with an estimated incidence of 1 in 20,000 live births and a carrier frequency of 1:70.
• Classic ARPKD is caused by biallelic pathogenic variants in the PKHD1 gene (located on chromosome 6), which encodes fibrocystin/polyductin (FPC), a large protein localized to the primary apical cilium, basal body, and endoplasmic reticulum.
• A rare, atypical form of ARPKD is caused by mutations in the DZIP1L gene, presenting with moderate cystic kidney disease but lacking clinically apparent liver involvement.
• Pathologically, the kidneys are massively enlarged and feature innumerable microcysts derived from ectatic, dilated collecting ducts radiating from the medulla to the cortex.
• ARPKD is a dual-organ disease characterized universally by congenital hepatic fibrosis (CHF) resulting from a ductal plate malformation, leading to bile duct proliferation, progressive hepatic fibrosis, and Caroli syndrome.

Clinical Manifestations

• The clinical spectrum is highly variable, with the most severe presentations diagnosed antenatally via the detection of bilaterally enlarged, hyperechoic kidneys and oligohydramnios.
• Neonates classically present with Potter sequence (oligohydramnios complex), characterized by pulmonary hypoplasia, flattened nose, micrognathia, low-set ears, and limb-positioning defects, leading to significant perinatal mortality from respiratory failure.
• Infants who survive the neonatal period frequently develop severe systemic hypertension requiring aggressive multi-drug therapy within the first few weeks of life.
• A subset of patients presents later in infancy or childhood with a predominantly hepatic phenotype, manifesting as portal hypertension, hepatosplenomegaly, gastroesophageal varices, hypersplenism (thrombocytopenia), and recurrent ascending cholangitis.
• Hyponatremia is frequently observed in the first weeks of life but is typically transient, while progressive decline in glomerular filtration rate (GFR) leads to end-stage kidney disease (ESKD) in approximately 50% of classical cases by 10 years of age.

Diagnostic Evaluation

• Prenatal and postnatal renal ultrasonography demonstrates bilaterally enlarged, reniform kidneys with uniformly increased echogenicity (a "salt and pepper" pattern) and loss of corticomedullary differentiation.
• High-resolution ultrasonography may reveal small elliptical cysts arranged radially in the medulla and cortex.
• Liver ultrasonography often reveals periportal echogenicity, intrahepatic bile duct dilatation, and macroscopic cysts consistent with Caroli disease.
• Diagnosis relies on the modified Zerres criteria, which combine typical renal imaging with clinical/pathological signs of congenital hepatic fibrosis, absence of renal cysts in parents, or a confirmed ARPKD sibling.
• Genetic testing with a comprehensive gene panel validates the diagnosis and distinguishes ARPKD from early-onset dominant forms or phenocopies.

Management

• Neonatal management is primarily supportive, often requiring aggressive mechanical ventilation for pulmonary hypoplasia and management of spontaneous pneumothorax.
• Strict blood pressure control is paramount; renin-angiotensin-aldosterone system (RAAS) blockade with angiotensin-converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs) serves as first-line therapy.
• Severe massive nephromegaly severely restricting diaphragmatic excursion or enteral feeding may necessitate early unilateral or bilateral nephrectomy.
• Dialysis (peritoneal or hemodialysis) and eventual kidney transplantation are required for ESKD, and select patients with severe portal hypertension or recurrent cholangitis may require combined liver-kidney transplantation.

Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Genetics and Pathophysiology

• Autosomal dominant polycystic kidney disease (ADPKD) is the most common hereditary kidney disease, affecting 1 in 400 to 1,000 individuals, and accounts for nearly 5% of all ESKD cases.
• The disorder is genetically heterogeneous; approximately 78% of cases are caused by mutations in the PKD1 gene (chromosome 16p13.3) encoding polycystin-1 (PC1), and 15% by mutations in the PKD2 gene (chromosome 4q22) encoding polycystin-2 (PC2).
• Emerging atypical genetic variants causing ADPKD include mutations in GANAB, DNAJB11, and ALG9, which often present with mild renal enlargement but significant interstitial fibrosis or polycystic liver disease.
• A contiguous gene deletion syndrome involving adjacent TSC2 and PKD1 genes causes a severe, very early-onset cystic phenotype with features of tuberous sclerosis.
• Pathophysiologically, defective polycystin function in the primary cilium alters intracellular calcium homeostasis, increases cyclic AMP (cAMP) levels, and upregulates the mechanistic target of rapamycin (mTOR) pathway.
• These cellular alterations drive abnormal tubular epithelial cell proliferation, fluid secretion (mediated by CFTR channels), and continuous cyst expansion from any segment of the nephron.

Clinical Manifestations in Childhood

• While ADPKD is traditionally considered an adult-onset disease, progressive structural kidney damage (cyst formation and kidney enlargement) begins in utero or early childhood.
• Hypertension is a frequent and early manifestation in children, affecting 20-40% of pediatric patients, and is associated with larger Total Kidney Volume (TKV) and faster disease progression.
• Masked hypertension and loss of nocturnal blood pressure dipping are common, making 24-hour ambulatory blood pressure monitoring (ABPM) a critical evaluation tool in pediatric ADPKD.
• Macroscopic or microscopic hematuria may occur due to cyst hemorrhage, nephrolithiasis, or urinary tract infections.
• Impaired urinary concentrating capacity leads to early polyuria, polydipsia, and nocturnal enuresis.
• Extrarenal manifestations include an increased left ventricular mass index (LVMI), early vascular dysfunction (increased pulse wave velocity), and mitral valve prolapse.
• Very Early Onset (VEO) ADPKD, diagnosed before 18 months of age, presents with massive nephromegaly and hypertension, mimicking ARPKD, and carries a high risk of progression to ESKD in childhood.

Diagnosis

• Renal ultrasonography is the primary screening modality, demonstrating bilaterally enlarged kidneys with multiple distinct macrocysts.
• For at-risk individuals aged 15 to 39 years with a positive family history, the presence of three or more unilateral or bilateral kidney cysts is sufficient for establishing an ADPKD diagnosis.
• Total Kidney Volume (TKV) measured via Magnetic Resonance Imaging (MRI) is the most reliable biomarker for predicting the risk of functional decline and chronic kidney disease progression.
• In families without a known history (de novo mutations occur in 8-10% of cases) or in children with VEO ADPKD, genetic panel testing is strongly advised to differentiate from ARPKD and other ciliopathies.

Management

• Lifestyle modifications include high water intake to suppress endogenous arginine vasopressin (AVP) production, dietary sodium restriction, and maintaining a normal body mass index.
• Strict blood pressure control is paramount to slow cardiovascular and renal progression; ACE inhibitors or ARBs are the preferred first-line agents, targeting a blood pressure below the 50th to 75th percentile for age, sex, and height.
• Tolvaptan, a vasopressin V2 receptor antagonist, decreases cAMP levels and has been shown to reduce TKV growth and GFR decline in rapidly progressive adult ADPKD; pediatric clinical trials are currently underway.
• Pravastatin (an HMG-CoA reductase inhibitor) has demonstrated efficacy in significantly slowing the progression of height-adjusted TKV in children and young adults with ADPKD.

Differential Diagnosis of Cystic Kidney Diseases